RGNX (Regenxbio) FFO


RGNX Regenxbio Inc RGNX
59 GF Score
Price $10.51
GF Value $13.81
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Regenxbio FFO?

FFO (Funds from operations) only applies to REITs.

RGNX
59GF Score
Regenxbio Inc RGNX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Regenxbio (RGNX) Overvalued in 2026?

Based on GuruFocus' analysis, Regenxbio stock appears to be undervalued. The current stock price of $10.51 is trading 23.9% below its estimated GF Value™ of $13.81. GuruFocus considers Regenxbio to be Modestly Undervalued.

Key valuation signals for RGNX:

  • FFO:
  • GF Value™: $13.81 vs. price of $10.51 (23.9% below fair value)
  • GF Score™: 59/100 with 8 warning signs

No single metric tells the full story. See the RGNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regenxbio Business Description

Other Exchanges RB0:Germany
Address 9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
59GF Score

Get the complete analysis for RGNX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.51
Price
$13.81
GF Value